Regeneron DRC A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
Research Grant
Administered By
Ophthalmology
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
September 23, 2019
End Date
October 1, 2022
Administered By
Ophthalmology
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
September 23, 2019
End Date
October 1, 2022